Literature DB >> 15339935

Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide: possible recognition of the fusion complex.

Doron Gerber1, Moshe Pritsker, Susanne Gunther-Ausborn, Benitra Johnson, Robert Blumenthal, Yechiel Shai.   

Abstract

The N-terminal fusion peptide (FP) of human immunodeficiency virus-1 (HIV-1) is a potent inhibitor of cell-cell fusion, possibly because of its ability to recognize the corresponding segments inside the fusion complex within the membrane. Here we show that a fusion peptide in which the highly conserved Ile(4), Phe(8), Phe(11), and Ala(14) were replaced by their d-enantiomers (IFFA) is a potent inhibitor of cell-cell fusion. Fourier transform infrared spectroscopy confirmed that despite these drastic modifications, the peptide preserved most of its structure within the membrane. Fluorescence energy transfer studies demonstrated that the diastereomeric peptide interacted with the wild type FP, suggesting this segment as the target site for inhibition of membrane fusion. This is further supported by the similar localization of the wild type and IFFA FPs to microdomains in T cells and the preferred partitioning into ordered regions within sphingomyelin/phosphatidyl-choline/cholesterol giant vesicles. These studies provide insight into the mechanism of molecular recognition within the membrane milieu and may serve in designing novel HIV entry inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339935     DOI: 10.1074/jbc.M403436200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Irregular structure of the HIV fusion peptide in membranes demonstrated by solid-state NMR and MD simulations.

Authors:  Dorit Grasnick; Ulrich Sternberg; Erik Strandberg; Parvesh Wadhwani; Anne S Ulrich
Journal:  Eur Biophys J       Date:  2011-01-28       Impact factor: 1.733

Review 2.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

3.  HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.

Authors:  Francisco J Quintana; Doron Gerber; Sally C Kent; Irun R Cohen; Yechiel Shai
Journal:  J Clin Invest       Date:  2005-07-07       Impact factor: 14.808

4.  Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome.

Authors:  Snehlata Tripathi; Binay Chaubey; Beverly E Barton; Virendra N Pandey
Journal:  Virology       Date:  2007-02-21       Impact factor: 3.616

Review 5.  Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides.

Authors:  Avraham Ashkenazi; Yechiel Shai
Journal:  Eur Biophys J       Date:  2011-01-22       Impact factor: 1.733

Review 6.  Candidate antibody-based therapeutics against HIV-1.

Authors:  Rui Gong; Weizao Chen; Dimiter S Dimitrov
Journal:  BioDrugs       Date:  2012-06-01       Impact factor: 5.807

7.  Effect of the HIV-1 fusion peptide on the mechanical properties and leaflet coupling of lipid bilayers.

Authors:  P Shchelokovskyy; S Tristram-Nagle; R Dimova
Journal:  New J Phys       Date:  2011-02       Impact factor: 3.729

8.  A critical evaluation of the conformational requirements of fusogenic peptides in membranes.

Authors:  Johannes Reichert; Dorit Grasnick; Sergii Afonin; Jochen Buerck; Parvesh Wadhwani; Anne S Ulrich
Journal:  Eur Biophys J       Date:  2006-11-07       Impact factor: 2.095

Review 9.  Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond.

Authors:  Ajit Monteiro; Karl O A Yu; Mark D Hicar
Journal:  Curr HIV Res       Date:  2021       Impact factor: 1.341

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.